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Insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2),
one of the most abundant circulating IGFBPs, is known to
attenuate the biological action of IGF-1. Although the effect
of IGFBP-2 in preventing metabolic disorders is well known,
its regulatory mechanism remains unclear. In the present study,
we demonstrated the transcriptional regulation of the Igfbp-2
gene by peroxisome-proliferator-activated receptor (PPAR) α in
the liver. During fasting, both Igfbp-2 and PPARα expression
levels were increased. Wy14643, a selective PPARα agonist,
significantly induced Igfbp-2 gene expression in primary cultured
hepatocytes. However, Igfbp-2 gene expression in Pparα null
mice was not affected by fasting or Wy14643. In addition, through
transient transfection and chromatin immunoprecipitation assay
in fasted livers, we determined that PPARα bound to the putative
PPAR-responsive element between − 511 bp and − 499 bp on the
Igfbp-2 gene promoter, indicating that the Igfbp-2 gene
transcription is activated directly by PPARα. To explore the
role of PPARα in IGF-1 signalling, we treated primary cultured
hepatocytes with Wy14643 and observed a decrease in the
number of IGF-1 receptors (IGF-1Rs) and in Akt phosphorylation.
No inhibition was observed in the hepatocytes isolated from
Pparα null mice. These results suggest that PPARα controls
IGF-1 signalling through the up-regulation of hepatic Igfbp-2
transcription during fasting and Wy14643 treatment.
Key words: fasting, gene expression, insulin-like growth factor-1
(IGF-1), insulin-like growth factor-binding protein 2 (IGFBP-2),
liver, peroxisome-proliferator-activated receptor α (PPARα).
INTRODUCTION
The insulin-like growth factor (IGF)-binding protein (IGFBP) is
known as a carrier protein for IGF-1 [1]. There are currently
seven characterized IGFBPs: IGFBP-1 to IGFBP [1]. IGFBPs
also function as modulators of IGF bioactivity and availability
[2]. The binding affinity of IGFBPs for IGFs is higher than that
of type I IGF receptors. The biological function of IGFBPs was
identified when it was demonstrated that IGFBPs are capable of
important biological roles that are independent of their ability to
bind to IGFs [3]. IGFBP-2, an abundantly secreted protein [4], is
expressed in the adult liver, adipocytes and central nervous system,
and plays a key role in the regulation of metabolic homoeostasis
and insulin sensitivity [5,6].
IGF-1 not only plays a key role in regulating growth and
development, but also has a variety of pathophysiological
functions related to cardiovascular disease, cancer, diabetes,
liver cirrhosis and Laron syndrome [7,8]. It is a single-chain
polypeptide hormone with endocrine, paracrine and autocrine
properties and is produced mainly in the liver. However, its
synthesis has also been shown to occur in a variety of other tissues,
such as the kidney, pancreas, skin and testes [7,9]. Because IGF-
1 shares structural homology with insulin and interacts with the
same membrane receptors [10], its key pathway is regulated by
the phosphoinositide-3-kinase (PI3K)–Akt–mTOR (mammalian
target of rapamycin), mitogen-activated protein kinase (MAPK)–
Ras–ERK (extracellular-signal-regulated kinase) and the Janus
kinase (JAK)–signal transducer and activator of transcription
(STAT) pathway [11]. Importantly, the bioactivity of IGF-1 is
effectively altered by high-affinity binding to IGFBP, which
subsequently attenuates IGF-1 activity [11,12]. At least six
IGFBPs are known to be involved in the expression and biological
activities of IGF-1 by binding to the IGF-1 receptor (IGF-1R)
[13]. IGF-1R consists of a α2β2 heterotetrameric complex with
extracellular α-subunits containing ligand-binding sites. Each
α-subunit of IGF-1R binds to one of two membrane-spanning
β-subunits with tyrosine kinase domains [14].
Peroxisome-proliferator activated receptor (PPAR)α is a
member of the superfamily of nuclear receptors that function
as transcription factors involved in the regulation of a variety of
metabolic processes, such as inflammation, insulin sensitivity and
glucose and lipid metabolism [15]. PPARα is highly expressed in
the liver and adipose tissue and is present in a diverse set of tissues
including the heart, kidney and intestines [15,16]. PPARα is
stimulated by ligands such as Wy14643 in addition to fenofibrate
and the fasting state, elevating fatty acid oxidation, ketogenesis,
bile acid synthesis and gluconeogenesis, as well as improving
inflammation and insulin sensitivity in response [16,17]. Previous
reports have shown that PPARα promotes apoptosis and inhibits
cellular functions by IGF-1R signalling and Akt phosphorylation
in various cancer cells [18–20]. Although PPARα is associated
with an IGF-1-dependent pathway in vitro, any potential link
between PPARα and IGF-1 signalling has yet to be determined in
an in vivo system.
Abbreviations: G6pc, glucose-6-phosphatase catalytic subunit; HEK, human embryonic kidney; IGF, insulin-like growth factor; IGF-1R, insulin-like growth
factor-1 receptor; IGFBP, insulin-like growth factor-binding protein; mTOR, mammalian target of rapamycin; Pck1, phosphoenolpyruvate carboxykinase
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In the present study, we identified PPARα as a key regulator
of Igfbp-2 gene transcription in the fasting state and revealed up-
regulation of IGFBP-2 by Wy14643 exposure. IGF-1 sensitivity
was prevented via down-regulation of the IGF-1-dependent
pathway under fasting in vivo and in vitro conditions. These
results suggest that regulation of the IGFBP-2–IGF-1 network by a
PPARα agonist may provide a novel molecular mechanism for im-
proving physiological changes via controlling IGF-1 bioactivity.
EXPERIMENTAL
Materials
Wy14643 (Sigma–Aldrich) and recombinant human IGF-1 (Life
Technologies) were dissolved in the recommended solvents.
Antibodies against p-IGF-1R, p-Akt, Akt, p-mTOR and p-S6
kinase (S6K) were purchased from Cell Signaling Technology
and anti-PPARα, IGFBP-2, IGF-1R and β-actin were from Santa
Cruz Biotechnology.
Experimental animals
Male C57BL6 mice (Jung-Ang Experimental Animals, Seoul,
Republic of Korea) and Pparα null mice at 8-weeks-old were
used in the experiments, as described previously [21]. For fasting
and feeding experiments, mice were fed or fasted for 24 h.
All animal experiments were performed in accordance with the
rules and regulations of the Institutional Animal Use and Care
Committee (IAUCC), Keimyung University School of Medicine.
Isolation and culture of primary mouse hepatocytes
Mouse primary hepatocytes were isolated from wild-type (WT)
and Pparα null mice. The hepatocytes were used for quantitative
PCR (qPCR) and immunoblot analyses. The hepatocyte isolation
method used was described previously [22].
qPCR analysis
Total RNA was isolated from mouse primary hepatocytes
and livers using the TRIzol method (Invitrogen). cDNA
was synthesized using a SuperScript III First-Strand cDNA
Synthesis kit (Invitrogen) and used for qPCR with LightCycler
Real-Time PCR systems (Roche Applied Science). All
data were normalized to ribosomal L32 expression. The
following primer sets were used: Pparα: forward, 5′-
AGAGCCCCATCTGTCCTCTC-3′; reverse, 5′-ACTGGTAG-
TCTGCAAAACCAAA-3′; Igfbp-1: forward, 5′-ATCAGC-
CCATCCTGTGGAAC-3′; reverse, 5′-TGCAGCTAATCTCTC
TAGCACTT-3′; Igfbp-2: forward, 5′-CAGACGCTACGCTG-
CTATCC-3′; reverse, 5′-CTCCCTCAGAGTGGTCGTCA-3′;
Pck1 (phosphoenolpyruvate carboxykinase 1): forward, 5′-
CCACAGCTGCTGCAGAACA-3′; reverse, 5′-GAAGGGTCG-
CATGGCAAA-3′; L32: forward, 5′-ACATTTGCCCTGAA-
TGTGGT-3′; reverse, 5′-ATCCTCTTGCCCTGATCCTT-3′; hu-
man Igfbp-2: forward, 5′-GACAATGGCGATGACCACTCA-3′;
reverse, 5′-CAGCTCCTTCATACCCGACTT-3′; human ACTB
(β-actin): forward, 5′-GGCATCCTCACCCTGAAGTA-3′.
Immunoblotting
Mouse primary hepatocytes were isolated and processed accord-
ing to a method described previously [21]. The membranes were
probed with the indicated antibodies and then developed using
an enhanced chemiluminescent Western blot detection kit (GE
Healthcare). The intensities of the bands were calculated using
ImageJ software (NIH), verifying non-saturation and subtracting
the background. Values are expressed as the integrals (target area
density) of each band (normalized to total indicated protein band).
ChIP assay
The ChIP assay was performed as described previously [21].
Briefly, mice were fasted for 24 h and refed for 12 h. Livers were
then collected from the mice and fixed with paraformaldehyde
for 5 min prior to performing the ChIP assay using anti-
PPARα. Liver tissue (25 mg) was used for each ChIP/antibody
sample. The final DNA extractions were quantified by PCR
with primers for the putative peroxisome-proliferator-responsive
element (PPRE; − 500/ − 300) region of the Igfbp-2 promoter.
PPRE on the glucose-6-phosphatase catalytic subunit (G6pc)
promoter was used as a positive control for the ChIP experiment
with an anti-PPARα antibody. Raw CT values obtained from
the ChIP samples were divided by CT values obtained from
the appropriate input samples to analyse the percentage input
values. The specific primers used for PCR were as follows:
mouse Igfbp-2c, forward 5′-TCATTACTTGCAGCGGTGAGC-
3′ and reverse 5′-CCGGGGAAACACAAAAGCAG-3′; mouse
G6pc-Ppre, forward 5′-GCTGTTTTTGTGTGCCTGTT-3′ and
reverse 5′-TGCTATCAGTCTGTGCCTTGG-3′; mouse Gapdh,
forward 5′-CCTGGAGAAACCTGCCAAGTA-3′ and reverse 5′-
TGGAAGAGTGGGAGTTGCTGT-3′.
ELISA for IGFBP-2
Serum was obtained from mice and primary hepatocytes. Secreted
IGFBP-2 was quantified using mouse serum and the Quantikine
mouse IGFBP-2 kit (Raybiotech). Serum (50 μl) was diluted with
50 μl of dilute buffer. Then, 80 μl of 12.5% 1 M formic acid and
87.5% ethanol mixture were added and incubated for 30 min
at room temperature to free IGFBP-2. The prepared samples
were used in each well of the Quantikine kit, as instructed in the
manual. Conditioned medium was assayed for secreted IGFBP-2
using the IGFBP-2 ELISA kit from RayBiotech, according to the
manufacturer’s protocol.
Statistical analysis
Results are expressed as means +− S.D. Differences between
groups were detected by one-way analysis of variance or a
paired Student’s t test. Differences were considered statistically
significant at P < 0.05.
RESULTS
Gene expression profiling in fasting compared with refeeding
conditions
To uncover the physiological relevance in the livers of fasted
and refed WT mice, we first evaluated general gene expression
profiles under different nutritional conditions. Previously, high-
throughput screening analysis in fasting and refed mouse livers
[23] had revealed that Igfbp-2 gene expression was higher in the
liver of fasting mice than refed mice liver (Figure 1A). Pparα,
Pck1 and Igfbp-2 mRNA levels were up-regulated in the fasting
mice, whereas Fasn (fatty acid synthase), Gck (Glucokinase) and
Srebf-1 (sterol regulatory element binding transcription factor-1)
mRNA were increased after refeeding.
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Figure 1 Microarray analysis to identify Igfbp-2 gene expression level and qPCR analysis in fasting condition
(A) Hierarchical gene clustering was generated with the TM4 Microarray Software Suite (MeV) from fasted and refed livers. A heat map showing significant changes in a group of selected genes
from the livers of mice that were fasted for 24 h and refed for 12 h. The ratios of gene profiles are presented as a heat map (left panel) and gene expression pattern (right panel). Fold change and
P-values of the genes in the clusters are given on the right. (B–E) mRNA levels of Igfbp-1, Igfbp-2, Pparα and Pck1 in the liver of WT mice were measured by qPCR under the indicated conditions.
**P < 0.01 and ***P < 0.001 compared with fed mice.
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To further evaluate the microarray data, we assessed qPCR
analysis in the livers of fed and fasted WT mice. As expected,
mRNA levels of Igfbp-2, Pparα and Pck1 were increased
significantly by the fasting state, relative to the fed state
(Figures 1B–1E). In contrast, Igfbp-1 gene expression was not
observed in fasted WT mice. Expression of other PPAR isoforms,
such as Pparγ 1, PPARγ 2 and PPARδ, did not change during
fasting (Figures 1F–1H). Overall, these findings demonstrated
that Igfbp-2 was up-regulated by the fasting condition.
Induction of IGFBP-2 by fasting and Wy14643 is dependent on
PPARα
Next, we examined whether PPARα plays a role in regulating
Igfbp-2 gene expression in primary cultured hepatocytes.
Wy14643 treatment in hepatocytes resulted in a significant
increase in the mRNA levels of Igfbp-2 and Pparα in a dose-
dependent manner, but did not affect Igfbp-1 (Figure 2A). In
addition, Wy14643 treatment increased Pparα mRNA levels
in the hepatocytes of WT mice but not in Pparα null mice
(Figure 2B). Moreover, Igfbp-2 mRNA expression increased in
fasting WT mice compared with fed or refed mice, in a fashion
similar to that shown in Figure 1. However, this phenomenon
was not observed in Pparα null mice (Figures 2C and 2D). Next,
we measured the level of secreted IGFBP-2 in the serum of WT
and PPARα null mice subjected to feeding and fasting. The level
of IGFBP-2 in the serum was increased in the fasted WT mice
(Figure 2E) but not in the Pparα null mice. This indicates that
IGFBP-2 secretion as well as mRNA expression of Igfbp-2 is
also increased by PPARα. In accordance with mRNA level, the
protein level of IGFBP-2 increased prominently in Wy14643-
treated WT mice. Again, this increase in protein level was not
observed in Wy14643-treated Pparα null mice (Figure 2F). Other
PPAR isoforms were not affected by Wy14643 treatment in the
primary hepatocytes (Figures 2G–2I). Collectively, these results
indicate that PPARα is a key mediator for up-regulating IGFBP-2
expression in primary cultured hepatocytes.
PPARα regulates the transcriptional activity of IGFBP-2
To identify the fundamental molecular mechanism through which
PPARα regulates Igfbp-2 gene transcription, the mouse Igfbp-2
(mIgfbp-2) gene promoter was transiently transfected into human
embryonic kidney (HEK)-293T-cells. As shown in Figure 3(A),
computer analysis with consensus PPRE sequence showed a
highly conserved putative PPRE on the Igfbp-2 promoter. A
proposed PPARα-binding element is shaded in the Igfbp-2
promoter between − 511 bp and − 499 bp. The transcriptional
activity of mIgfbp-2 in response to Wy14643 treatment was
highest with a full-length gene promoter and was diminished
markedly with deletion up to − 444 bp (Figure 3B). Moreover,
internal deletion of the putative PPRE between − 511 bp and
− 499 bp from the full-length mIgfbp-2 resulted in decreased
promoter activity (Figure 3C). These data collectively suggest that
the putative PPRE is located between the − 511 and − 499 bp
regions of the mIgfbp-2 gene promoter. We next performed ChIP
assays in mouse livers to verify PPARα binding to the mIgfbp-
2 gene promoter at the chromatin level. PPARα occupancy was
greater on the mIgfbp-2 promoter (Figure 3D). A known PPRE
region on the G6pc gene promoter was used as a positive control
in the ChIP assay (Figure 3E). These results demonstrate that
Igfbp-2 gene expression is regulated through the direct binding of
PPARα to the Igfbp-2 promoter.
IGF-1 signalling is altered by PPARα in primary cultured
hepatocytes
To determine the role of PPARα on hepatic IGF-1 signalling,
we treated hepatocytes of WT and Pparα null mice with IGF-1
and/or Wy14643. IGF-1-induced phosphorylation of IGF-1R and
Akt were decreased significantly by Wy14643 in WT mice and the
inhibitory effect of Wy14643 was abolished in Pparα null mice
(Figure 4). These findings suggest that PPARα may play a negative
role in IGF-1 signal transduction in primary hepatocytes.
IGFBP-2 expression is not affected by PPARγ agonist
Finally, we asked whether Igfbp-2 expression was up-regulated
by Pparγ agonists. Rosiglitazone, a PPARγ agonist, was added
to primary hepatocytes for 6 h and Igfbp-2 mRNA levels were
measured. As shown in Figure 5(A), Igfbp-2 expression was not
up-regulated by rosiglitazone in primary hepatocytes of WT or
Pparα null mice. Treatment with rosiglitazone in the HepG2
cell line also showed minor effects (Figure 5B). These findings
indicate that Pparγ is not involved in Igfbp-2 expression.
DISCUSSION
In the present study, we have shown that the fasting state
and Wy14643 exposure elevated Igfbp-2 gene transcription
and secretion by promoting PPARα in primary hepatocytes,
inhibiting IGF-1 signalling and attenuating an IGF-1-dependent
pathway. However, the inhibitory action of Wy14643 on the
IGF-1 signalling pathway was disrupted in Pparα null mice.
Our study showed that Wy14643 exposure increased Igfbp-2
gene transcription through PPARα recruitment. Based on these
findings, we propose that up-regulation of Pparα by physiological
changes and ligand exposure may prevent hepatic IGF-1
signalling by activating Igfbp-2 expression.
Changes in IGFBP-2 levels are associated with various
physiological and pathological states, such as exercise, pregnancy,
aging, hormones, diabetes, obesity, insulin resistance and tumours
[24–26]. Previous studies have shown that expression of the
Igfbp-2 gene is promoted significantly in the liver during
fasting [27,28] and that insulin markedly attenuates Igfbp-2 gene
expression in myoblast cells and in the heart [29,30]. These
findings suggest that IGFBP-2 is altered by physiological states
and insulin. However, the biological link between IGFBP-2 and
other transcription factors in response to fasting states has not been
fully addressed. Our results demonstrate that fasting states elevate
IGFBP-2 and PPARα significantly compared with feeding states
(Figures 1C and 1D). Remarkably, fasting states and Wy14643
treatment effectively promoted Igfbp-2 gene expression in WT
mice, but not in Pparα null mice (Figure 2C). These findings
suggest that IGFBP-2 may be involved in fasting conditions and
that Wy14643 plays an important role in controlling Igfbp-2 gene
expression in primary hepatocytes.
As mentioned previously, PPARα acts as a key regulator of
diverse metabolic processes and also of metabolic homoeostasis
[15,16,31]. It has been shown that PPARα reduced cellular
functions by attenuating IGF-1R and Akt activity in diverse
cancer cells [18–20]. However, there is no evidence of a
correlation between PPARα and the IGF-1 signalling system
in primary hepatocytes. Our findings reveal a novel action of
PPARα involving IGF-1 sensitivity via the IGF-1R–Akt signalling
pathway. Our results demonstrate that the stimulation of IGF-1R,
Akt, mTOR and S6K activity by IGF-1 exposure is markedly
decreased by Wy14643 treatment. The inhibitory effects of
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 2 PPARα is involved in the induction of IGFBP-2 following the fasting state and Wy14643 treatment
(A) Mouse primary hepatocytes were treated with Wy14643 (Wy) for 6 h at the indicated concentrations. Total RNA was isolated and analysed using qPCR with the observed primers. (B) Mouse
primary hepatocytes from WT and Pparα null mice were treated with or without Wy14643 for 6 h. The level of Pparα mRNA was measured by qPCR analysis. (C) The mRNA level of Igfbp-2 in liver
from WT and Pparα null mice fed and fasted for 24 h was analysed by qPCR. (D) Protein level of IGFBP-2 in livers from WT and Pparα null mice fed and fasted for 24 h was analysed by Western
blot analysis. (E) Secretion level of IGFBP-2 in vivo and in vitro. Mice were fed or fasted for 24 h and serum was collected from WT and Pparα null mice. Secretion levels of IGFBP-2 in feeding or
fasting conditions were measured by ELISA. (F) WT and Pparα null mice were treated with or without Wy14643 for 6 h. Whole cell extracts were isolated from primary hepatocytes of the observed
conditions and assessed by Western blot analysis with the indicated antibody. (G–I) Primary hepatocytes from WT and Pparα null mice were treated with or without Wy14643 for 6 h. The level of
Pparγ1, PPARγ2 and PPARδ mRNA was measured by qPCR analysis. *P < 0.05 and **P < 0.01 compared with untreated control or fed WT mice.
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 3 Identification of PPRE in the mIgfbp-2 promoter
(A) Comparison of putative PPRE with consensus PPRE sequences. A proposed PPARα-binding element is shaded on the Igfbp-2 promoter between − 511 and − 499. The numbers indicate the
distance in nucleotides from the transcription start site ( + 1) of the mouse Igfbp-2 gene. (B) Effects of PPARα on promoter reporter activities in deletion constructs of the Igfbp-2 gene. Deletion
construct of the mIgfbp-2 promoter was transiently co-transfected with pcDNA3 (open bars) or PPARα expression vector (closed bars) in HEK-293T cells. After 24 h, media were changed to contain
20 μM Wy14643. Luciferase activity was normalized to β-galactosidase activity to correct for transfection efficiency. (C) Internal deletion constructs for the Igfbp-2 promoter were analysed for
promoter activity. (D and E) ChIP assay. Mice were fasted for 24 h and refed for 12 h. Chromatins were isolated from mice livers and ChIP assay was performed. Input represents 10 % of purified DNA
in each sample. Nuclear extracts from mice livers were immunoprecipitated with anti-PPARα antibody and purified DNA samples were used to perform qPCR with primers binding to the putative
PPRE regions on the mIgfbp-2 (D) and mG6pc (E) gene promoters. All data are representative of at least three independent experiments. *P < 0.05 compared with untreated control.
Wy14643 were disrupted in PPARα null mice. Thus, PPARα
may protect against IGF-1 sensitivity by attenuating the IGF-1-
dependent pathway in primary hepatocytes.
It is well known that PPARα regulates the transcription of
various target genes [16,21,32,33]. Although our results identify a
novel link between PPARα and IGFBP-2 in primary hepatocytes,
we do not rule out the possibility that PPARα may rely on
other as-yet-unknown mechanisms that control the involvement
of transcription co-activators or the completion of co-repressors,
protein degradation and modification. Thus, further study is
required to determine the detailed molecular network of PPARα
and IGFBP-2 in primary hepatocytes.
Ppar isoforms activate target gene expression by binding
to the PPRE on the promoter region(s) of target genes [34]. Among
the various Ppar isoforms, Pparα expression is increased in the
liver during fasting, resulting in the stimulation of Igfbp-2
c© The Authors Journal compilation c© 2015 Biochemical Society
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Figure 4 The IGF-1 signalling system is mediated by PPARα in primary hepatocytes
WT and Pparα null mice were pretreated with Wy14643 for 6 h and then exposed to IGF-1 for 15 min under the indicated conditions. Whole cell extracts were isolated from primary hepatocytes of
the indicated groups and assessed by Western blot analysis with various antibodies. Right panel indicate the density of Western blot bands measured with ImageJ software. *P < 0.05 compared with
untreated control or IGF-1-treated cells and #P < 0.05 compared with IGF-1- and Wy14643-treated cells.
Figure 5 Effects of PPAR agonists in the primary hepatocytes and hepatic
cell lines
(A) Effect of rosiglitazone on Igfbp-2 gene expression. Rosiglitazone (10 μM) was added to
primary hepatocytes for 6 h and RNA was harvested for qPCR. (B) mRNA levels of Igfbp-2 after
rosiglitazone or Wy14643 treatment in the HepG2 cell line. Rosiglitazone (10 μM) or Wy14643
(10 μM) was added to HepG2 cells for 6 h and RNA was harvested for qPCR. Values are
expressed as mean values +− S.E.M. from three experiments. Rosi, rosiglitazone; Wy, Wy14643.
*P < 0.05 compared with untreated group.
expression and the secretion of IGFBP-2. In the present study,
we demonstrated that Pparα was the only PPAR isoform induced
in fasted liver (Figures 1 and 5). Additionally, because PPARγ
expression is very low in the liver during fasting, PPARγ may
be not involved in the stimulation of Igfbp-2 gene transcription.
These results indicate that IGFBP-2 is primarily regulated in the
liver by PPARα during fasting.
In conclusion, we have shown that the fasting state promotes
Igfbp-2 gene expression by up-regulating PPARα and that
the PPARα–IGFBP-2 cascade attenuates IGF-1 sensitivity by
controlling the IGF-1 signalling network. Our findings provide
evidence of a novel pathway involved in the regulation of the
hepatic IGFBP-2–IGF-1 network and/or PPARα in the fasting
state as well as a potential therapeutic approach for the treatment
of hepatic metabolic disorders.
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